Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Medtronic
McKesson
AstraZeneca
Boehringer Ingelheim

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

EOVIST Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Eovist patents expire, and when can generic versions of Eovist launch?

Eovist is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-four countries.

The generic ingredient in EOVIST is gadoxetate disodium. One supplier is listed for this compound. Additional details are available on the gadoxetate disodium profile page.

Summary for EOVIST
Drug patent expirations by year for EOVIST
Drug Prices for EOVIST

See drug prices for EOVIST

Generic Entry Opportunity Date for EOVIST
Generic Entry Date for EOVIST*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EOVIST

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Research Foundation of KoreaPhase 4
Seoul National University HospitalPhase 4
University of California, San DiegoPhase 4

See all EOVIST clinical trials

Pharmacology for EOVIST
Synonyms for EOVIST
135326-22-6
2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid; gadolinium(3+)
222726-20-7
AC1L9OPS
Bay 86-4873
BCP09445
Disodium (N-((2S)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))gadolinate(2-)
Eovist injection
Gadolinate(2-), (N-(2-(bis((carboxy-kappaO)methyl)amino-kappaN)-3-(4-ethoxyphenyl)propyl)-N-(2-(bis((carboxy-kappaO)methyl)amino-kappaN)ethyl)glycinato(5-)-kappaN,kappaO)-, disodium, (SA-8-11252634-(S))-
Gadolinium EOB DTPA
Gadolinium Ethoxybenzyl Dtpa
gadolinium ethoxybenzyl-DTPA
gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid, disodium S-[4-(4-ethoxybenzyl)-3,6,9-tris[(carboxy-KO)methyl]-3,6,9-triazaundecandioato)(5-)-K3N3,N6,N9,K2O1,O11]gadolinite(2-)
gadoxate disodium
Gadoxetate Disodium
Gadoxetate Disodium [USAN]
Gadoxetic acid disodium
Gd-(S)-EOB-DTPA
HOY74VZE0M
HSDB 8233
MOLI000482
Primovist
UNII-HOY74VZE0M
ZK 139834

US Patents and Regulatory Information for EOVIST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-001 Jul 3, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-002 Feb 4, 2013 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for EOVIST

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0405704 C00405704/01 Switzerland   Start Trial FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE
0405704 SPC/GB05/021 United Kingdom   Start Trial PRODUCT NAME: GADOXETIC ACID, OPTIONALLY IN THE FORM OF A SALT; REGISTERED: SE 18929 20040326; SE 18930 20040326; UK PL 00053/0348 20041110; UK PL 00053/0349 20041110
0405704 300182 Netherlands   Start Trial 300182, 20100627, EXPIRES: 20150626
0405704 C300182 Netherlands   Start Trial PRODUCT: GADOXETINEZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER HET NATRIUMZOUT. FIRST AUTHORIZATION NO/DATE: 1829 AND 18930, 20040326 (SE); NATIONAL AUTHORIZATION NO/DATE: RVG 31393 AND 31394, 20050113
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.